Cargando…
When Should We Adopt EUS-Guided Radiofrequency Ablation in Pancreatic Neuroendocrine Tumors?
Autores principales: | Marasco, Matteo, Galasso, Domenico, Larghi, Alberto, Panzuto, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380401/ https://www.ncbi.nlm.nih.gov/pubmed/37510695 http://dx.doi.org/10.3390/jcm12144581 |
Ejemplares similares
-
EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat?
por: Larghi, Alberto, et al.
Publicado: (2019) -
EUS-guided radiofrequency ablation of a pancreatic neuroendocrine tumor
por: Dawod, Qais, et al.
Publicado: (2020) -
EUS-guided radiofrequency ablation: Where we are?
por: Okasha, Hussein Hassan, et al.
Publicado: (2020) -
EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: A systematic review and meta-analysis
por: Garg, Rajat, et al.
Publicado: (2022) -
Long-term outcome after EUS-guided radiofrequency ablation: Prospective results in pancreatic neuroendocrine tumors and pancreatic cystic neoplasms
por: Barthet, Marc, et al.
Publicado: (2021)